Nektar Therapeutics (NASDAQ:NKTR) Q1 2024 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Nektar Therapeutics First Quarter 2024 Financial Results Conference Call. [Operator Instructions].
Nektar Therapeutics (NKTR)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Deep Track Capital David Kroin | 18,400,000 | $17,189,280 | 0.49% | |
| 2. | Stonepine Capital Timothy P. Lynch | 3,480,409 | $3,251,398 | 2.57% | |
| 3. | Citadel Investment Group Ken Griffin | 3,193,714 | $2,983,568 | -44% | 0% |
| 4. | Millennium Management Israel Englander | 2,984,545 | $2,788,162 | +87% | 0% |
| 5. | D E Shaw D. E. Shaw | 2,548,990 | $2,381,267 | -38% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $17.28 | 15,000 | Officer | 107,668 | 2019-09-05 | Filing | |
| $59.80 | 1,400 | Director | 177,000 | 2018-06-06 | Filing | |
| $59.07 | 2,000 | Director | 175,600 | 2018-06-06 | Filing | |
| $55.22 | 1,600 | Director | 173,600 | 2018-06-05 | Filing | |
| $17.95 | 35,000 | Director | 133,000 | 2017-08-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.20 | 19,500 | 255,273 | 2024-06-14 | Filing | ||
| $1.75 | 16,650 | 863,239 | 2024-05-17 | Filing | ||
| $1.75 | 7,355 | 257,670 | 2024-05-17 | Filing | ||
| $1.75 | 6,260 | 230,414 | 2024-05-17 | Filing | ||
| $1.78 | 56,000 | 18,344,000 | 2024-05-10 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 12,042,873 | $6,804,223 | 0% | |
| 2. | 7,001,747 | $3,955,987 | 0% | |
| 3. | 6,104,217 | $3,448,882 | 0% | |
| 4. | 5,973,387 | $3,374,964 | 0.99% | |
| 5. | 3,404,165 | $1,923,353 | 0% |
News See All
Nektar Therapeutics (NASDAQ:NKTR) Q4 2023 Earnings Call Transcript
Nektar Therapeutics misses on earnings expectations. Reported EPS is $-0.22 EPS, expectations were $-0.2.
Nektar Therapeutics (NASDAQ:NKTR) Q3 2023 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to the Nektar Therapeutics Third Quarter 2023 Financial Results Conference Call.
12 Best Penny Stocks to Buy Under $1
Investors are optimistic as we move into the third quarter earnings season.
Nektar Therapeutics (NASDAQ:NKTR) Q2 2023 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to the Nektar Therapeutics Second Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Nektar Therapeutics (NASDAQ:NKTR) Q1 2023 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to the Nektar Therapeutics First Quarter 2023 Financial Results Conference Call.
Analysts Are Downgrading These 10 Pharmaceutical Stocks
In this article, we present the 10 pharmaceutical stocks that are being downgraded by analysts.
Billionaire Stanley Druckenmiller Just Dumped These 10 Stocks
In this article, we look at why billionaire Stanley Druckenmiller just dumped 10 stocks from his portfolio.
5 Healthcare Stocks to Buy According to Lee Ainslie's Maverick Capital
In this piece, we will take a look at the 5 healthcare stocks to buy according to Lee Ainslie's Maverick Capital. If you want to learn more about Mr.
Should I Buy Nektar Therapeutics (NKTR)?
Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns.
Billionaire Hedge Funds
